On May 14, 2026, Plus Therapeutics, Inc. held its Annual Meeting where stockholders elected directors, ratified an accounting firm, approved executive compensation, and amended the stock incentive plan. 64,857,321 shares were represented, with director Howard Clowes receiving 11,863,579 votes for his election.